Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction

American Journal of Cardiology

Volumn 98, Issue 6, 2006, Pages 758-760

  Dagenais, Gilles R ^a   Pogue, Janice ^b   Teo, Koon K ^b   Lonn, Eva M ^b   Yusuf, Salim ^b  

^a LAVAL UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CIRCADIAN RHYTHM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYOCARDIAL INFARCTION; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS;

EID: 33748140762     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.03.061     Document Type: Article

References (12)

1. Muller J.E., Stone P.H., Turi Z.G., Rutherford J.D., Czeisler C.A., Parker C., Poole K., Passamani E., Roberts R., Robertson T., et al., MILLIS Study Group. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313 (1985) 1315-1322
2. Willich S.N., Linderer T., Wegscheider K., Leizorovicz A., Alamercery I., Schröder R., and ISAM Study Group. Increased morning incidence of myocardial infarction in the ISAM study; absence with prior β-adrenergic blockade. Circulation 80 (1989) 853-858
3. Cannon C.P., McCabe C.H., Stone P.H., Schactman M., Thompson B., Theroux P., Gibson R.S., Feldman T., Kleiman N.S., Tofler G.H., et al., TIMI III Registry and TIMI IIIB Investigators. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI III B). Am J Cardiol 79 (1997) 253-258
4. Cohen M.C., Rothla K.M., Lavery C.E., Muller J.E., and Mittleman M.A. Meta-analysis of the morning excess of acute myocardial infarction and sudden death. Am J Cardiol 79 (1997) 1512-1516
5. Manfredini R., Boari B., Bressan S., Gallerani M., Salmi R., Portaluppi F., and Metha R.H. Influence of circadian rhythm on mortality after myocardial infarction: data from a prospective cohort of emergency calls. Am J Emerg Med 22 (2004) 555-559
6. Ridker P.M., Manson J.E., Buring J.E., Muller J.E., and Hennekens C.H. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 82 (1990) 897-902
7. HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple, randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 12 (1996) 127-137
8. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
9. Giles T. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 23 suppl 1 (2005) S35-S39
10. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
11. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trial. Prog Cardiovasc Dis 27 (1985) 335-371
12. Dagenais G.R., Yusuf S., Bourassa M.G., Yi Q., Bosch J., Lonn E.M., Kouz S., and Grover J. Effects of ramipril on coronary events in high-risk persons: results from the HOPE Study. Circulation 104 (2001) 522-526